Group B Streptococcus Screening in Pregnant Women: A Belgian Multicentre Study Evaluating the Predictive Window of Antenatal Screening With Real-time PCR
This Belgian multicentre study demonstrates that broth-enriched real-time PCR is superior to culture and non-enriched PCR for antenatal Group B Streptococcus screening, identifying a predictive window of 3.5 to 4 weeks before delivery (36–38 weeks of gestation) that optimizes the accuracy of predicting maternal colonization at birth.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, a common bacterium that lives harmlessly in the intestines and vagina of many adults poses a hidden threat to newborns. This bacterium, known as Group B Streptococcus, can pass from a mother to her baby during childbirth. If the baby is exposed, it can develop a severe infection within the first week of life, leading to serious conditions like blood poisoning, pneumonia, or inflammation of the brain. To prevent this, doctors routinely screen pregnant women late in their pregnancy to see if they carry the bacteria. If a woman tests positive, she receives antibiotics during labor to protect the baby. The challenge lies in timing: because the presence of this bacterium can change from week to week, a test done too early might miss a new infection, while a test done too late might miss a woman who has already cleared the bacteria. Finding the perfect window to test is crucial for ensuring every at-risk baby is protected without giving unnecessary medication to mothers who no longer carry the bacteria.
A team of researchers across three hospitals in Belgium set out to solve this timing puzzle using a modern, highly sensitive testing method. Instead of the traditional approach of growing bacteria in a lab dish, which can take days and sometimes misses low levels of infection, they used a rapid molecular test that detects the genetic material of the bacteria directly. This method, called real-time PCR, is like a highly sensitive scanner that can find the bacteria's DNA even when there is very little of it present. The researchers wanted to know exactly how far in advance of delivery this test could be trusted. They asked a simple but vital question: if a woman tests positive or negative at 35 or 36 weeks, how long does that result remain accurate as she moves closer to her due date?
To answer this, the study involved over 1,300 pregnant women who were screened between 35 and 37 weeks of gestation. The researchers collected samples from the vagina and rectum and analyzed them in three different ways to see which method was best. They compared the standard rapid test without any preparation, the same test after the sample was allowed to grow in a nutrient broth for a day or two, and the traditional method of growing the bacteria on a special agar plate. The results showed that the rapid test worked significantly better when the sample was first enriched in the broth. This enriched test found more cases of the bacteria than the traditional culture method, proving that the molecular scanner is a more powerful tool for spotting the infection early.
The core of the study then focused on the "predictive window," which is the maximum amount of time a test result can be relied upon before delivery. The researchers followed a subset of 257 women who provided a second sample just before they gave birth. By comparing their early test results with their final status at delivery, the team could see how often the bacteria appeared or disappeared in the weeks leading up to birth. They found that the bacteria's presence is indeed dynamic; about 7.7 percent of women who carried the bacteria at the time of their early screening had lost it by the time they delivered, meaning they would have received unnecessary antibiotics. Conversely, 3.9 percent of women who tested negative early on had acquired the bacteria by the time they gave birth, putting their babies at risk if no antibiotics were given.
Using statistical analysis to track these changes, the researchers determined that the test results remain highly reliable for a specific period. They found that if a woman is screened between 3.5 and 4 weeks before her expected delivery date, the result is accurate enough to guide treatment decisions with a high degree of confidence. Specifically, the study showed that the status of the bacteria remained stable in more than 95 percent of women up to 3.7 weeks before birth. This suggests that the current standard of testing between 35 and 37 weeks of pregnancy is well-placed, as it falls squarely within this reliable window. The data indicates that screening at this time captures the vast majority of women who will be carrying the bacteria during labor, while minimizing the number of women who are treated unnecessarily because they have already cleared the infection.
The study also highlighted that while the molecular test is superior in sensitivity, it is not perfect. There is a small chance that a woman who tests positive might not actually be carrying the bacteria at the moment of delivery, leading to unnecessary treatment. However, the researchers noted that the risk of missing a new infection is considered more dangerous than the risk of over-treating, which supports the use of this screening window. The findings suggest that the combination of the enriched molecular test and a screening schedule of 36 to 38 weeks of gestation offers the best balance for protecting newborns. While the study confirms that the bacteria can appear and disappear quickly, the data provides a clear, evidence-based timeframe for when doctors should look for it, ensuring that the right mothers receive the right protection for their babies at the right time.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.